http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106434553-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e203c5820fb3c0bea65190498d3f8894 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2302 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-2301 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-24 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0646 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate | 2016-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fbcb91be982b93e9c24f4bb8295569ef http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cff1ce512cba1de252aed511693f3853 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c6efaf2edba89b82ba021cb80fb4f36c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1cf762f042451af895893aa08a185ca6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c2bcb139a106fcaac91ebc0b583ede7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ffc3e4494c62d481bf37b887642759c |
| publicationDate | 2017-02-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-106434553-A |
| titleOfInvention | Method for co-stimulation amplification of human NK cells through combining Tlr4 and Tlr7 stimulants |
| abstract | The invention provides a method for co-stimulation amplification of human NK cells through combining Tlr4 and Tlr7 stimulants. The NK cells are highly-active lymphocytes population separated from peripheral blood, a series of cell factors, Tlr4a (MPLA) and Tlr7a (GD) are added to an in-vitro culture system, and cocktail type culture is carried out to activate and massively amplify the NK cells (CD3-CD56+) in order to reach application to clinic treatment of tumors. The NK cells prepared through the method have an obviously higher tumor target cell killing effect than common NK cells. The method allows a large amount of safe NK cells with high killing activity to be obtained under in-vitro culture conditions, and also has the advantages of low preparation cost, simple process, easiness in control of conditions, low device requirements, and easiness in large-scale production. The invention also provides an induction culture system for in-vitro preparation of the NK cells. The NK cells (Tlr4a-Tlr7a-NK) prepared through the method can be used to treat cancer patients or prevent cancer high-risk populations and prevent viruses. |
| priorityDate | 2016-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 38.